## ABT: Abbott Laboratories - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.6% below STRENGTH zone (3.0-6.0%); PEG 4.17 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($123.38)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Abbottâ€™s New Libre Assist AI Tool Might Change The Case For Investing In Abbott Laboratories (ABT)**
- Source: Simply Wall Street | 20260106T162728 | Somewhat-Bullish | Relevance: 100%
- Abbott Laboratories recently launched Libre Assist, an AI-powered feature for its Libre diabetes app, which helps U.S. users predict and understand meal impact on glucose levels. This move aims to evolve the FreeStyle Libre into a comprehensive diabetes management platform. While Libre Assist signals Abbott's push into software-centered solutions, its near-term financial impact is expected to be modest, with the upcoming Q4 2025 earnings call being a key event for investors to assess the company's strategic direction and address competitive pressures in the continuous glucose monitoring market.

**2. Abbott Laboratories (NYSE:ABT) Given New $144.00 Price Target at Evercore ISI**
- Source: MarketBeat | 20260106T143935 | Bullish | Relevance: 100%
- Evercore ISI has increased its price target for Abbott Laboratories (NYSE:ABT) to $144.00 from $142.00, reiterating an "outperform" rating and implying a potential 13.65% upside. The healthcare company also received a consensus "Moderate Buy" rating from analysts with an average target of $147.47. This news comes after Abbott reported Q3 EPS of $1.30 and revenue of $11.37 billion, and set FY2025 guidance between $5.120 and $5.180 EPS.

**3. Abbott Laboratories $ABT Shares Sold by Commonwealth Equity Services LLC**
- Source: MarketBeat | 20260106T090757 | Somewhat-Bullish | Relevance: 100%
- Commonwealth Equity Services LLC reduced its stake in Abbott Laboratories (NYSE:ABT) by 5.1% in Q3, selling 42,211 shares, though it still holds 789,908 shares valued at $105.8 million. Meanwhile, other major institutional investors like Vanguard and State Street increased their positions, with institutional investors collectively owning 75.18% of the stock. Abbott reported Q3 EPS in line with estimates and raised its quarterly dividend, while analysts maintain a "Moderate Buy" consensus rating with an average target price of $147.37.

**4. Abbott Laboratories Stock Gains Momentum from AI and Analyst Confidence**
- Source: AD HOC NEWS | 20260105T211210 | Bullish | Relevance: 100%
- Abbott Laboratories is experiencing renewed market interest due to new product announcements, including an AI-powered feature for its diabetes care platform, and positive analyst revisions. The company reported strong Q4 2025 revenue growth of 6.9% and increased its quarterly dividend for the 54th consecutive year. Analysts from Barclays and Evercore ISI have raised their price targets, indicating a positive outlook for the company, despite a significant reduction in holdings by Railway Pension Investments.

**5. Abbott unveils new FreeStyle Libre app feature for mealtime decisions**
- Source: MassDevice | 20260105T170153 | Bullish | Relevance: 100%
- Abbott has launched Libre Assist, a new feature within its FreeStyle Libre app designed to help people with diabetes understand how different foods impact their glucose levels. Unlike traditional food logging apps, Libre Assist provides feedback before meals, enabling more informed dietary choices. This new offering was unveiled at CES 2026 and provides a similar functionality to Dexcom's AI-powered meal logging system.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | Barclays | $169 | $162 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.39M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.2%)
- Blackrock Inc.: 8.1% (+0.2%)
- State Street Corpora: 4.5% (-0.2%)
- Capital Internationa: 3.5% (+2.5%)
- JPMORGAN CHASE & CO: 3.4% (+49.5%)

### Key Risks

1. Valuation stretched: PEG 4.2x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +1.7% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 4.17 signals overvaluation risk, limited margin of safety. Forward P/E 22.5x stretched relative to 10% growth. Quality metrics strong (ROE 31%, margin 32%). Balance sheet: $2.3B free cash flow. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $222.4B |
| Beta | 0.72 |
| 52W Range | $110.86 - $141.23 |
| Short Interest | 0.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.17 |
| Forward P/E | 22.5 |
| Current P/E | 24.7 |
| YoY Growth | 9.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -0.1% to 1.6% (+1.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.4pp (needs >3.0% for momentum thesis). MRS_5 at 0.8% confirms short-term momentum alignment. Below SMA200 (0.98x), long-term trend not supportive. RSI neutral at 57. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.57% (CS: 54) | Neutral |
| RSI_14 | 57.4 | Neutral |
| MACD Histogram | 0.31 | Bullish |
| vs SMA20 | 1.022x | Above |
| vs SMA50 | 1.014x | Above |
| vs SMA200 | 0.983x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $127.84
- **Stop Loss:** $123.38 (3.5% risk)
- **Target:** $132.30 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 295
- **Position Value:** $37,712.80
- **Portfolio %:** 37.71%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-01-21 (Est: $1.50)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.30 | $1.30 | +0.1% |
| 2025Q2 | $1.26 | $1.26 | +0.3% |
| 2025Q1 | $1.07 | $1.09 | +1.7% |
| 2024Q4 | $1.34 | $1.34 | -0.2% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*